The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A new peptide vector for efficient delivery of oligonucleotides into mammalian cells
Open accessAbstract
The development of antisense and gene therapy has focused mainly on improving methods for oligonucleotide and gene delivery into cells. In the present work, we describe a potent new strategy for oligonucleotide delivery based on the use of a short peptide vector, termed MPG (27 residues), which contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain derived from the nuclear localization sequence of SV40 T-antigen. The formation of peptide vector/oligonucleotide complexes was investigated by measuring changes in intrinsic tryptophan fluorescence of peptide and of mansyl-labelled oligonucleotides. MPG exhibits relatively high affinity for both single- and double-stranded DNA in a nanomolar range. Based on both intrinsic and extrinsic fluorescence titrations, it appears that the main binding between MPG and oligonucleotides occurs through electrostatic interactions, which involve the basic-residues of the peptide vector. Further peptide/peptide interactions also occur, leading to a higher MPG/oligonucleotide ratio (in the region of 20/1), which suggests that oligonucleotides are most likely coated with several molecules of MPG. Premixed complexes of peptide vector with single or double stranded oligonucleotides are delivered into cultured mammalian cells in less than 1 h with relatively high efficiency (90%). This new strategy of oligonucleotide delivery into cultured cells based on a peptide vector offers several advantages compared to other commonly used approaches of delivery including efficiency, stability and absence of cytotoxicity. The interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and crossing of the plasma membrane. The mechanism of cell delivery of oligonucleotides by MPG does not follow the endosomal pathway, which explains the rapid and efficient delivery of oligonucleotides in the nucleus. As such, we propose this peptide vector as a powerful tool for potential development in gene and antisense therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978
Current protocols in molecular biology
(1988) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(88)90131-4 · Cited by 4,160
Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations.
Felgner, J. H., Kumar, R., Sridhar, C. N., Wheeler, C. J., Tsai, Y. J., Border, R., Ramsey, P., Martin, M., & Felgner, P. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41980-6 · Cited by 1,312
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C. A., & Cheng, Y.-C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,303
Sequence requirements for nuclear location of simian virus 40 large-T antigen
Kalderon, D., Richardson, W. D., Markham, A. F., & Smith, A. E. (1984) · Nature · doi:10.1038/311033a0 · Cited by 1,286
Nucleotide sequence of the AIDS virus, LAV
Wain-Hobson, S., Sonigo, P., Danos, O., Cole, S., & Alizon, M. (1985) · Cell · doi:10.1016/0092-8674(85)90303-4 · Cited by 1,202
Cyclin a is required for the onset of DNA replication in mammalian fibroblasts
Girard, F., Strausfeld, U., Fernandez, A., & Lamb, N. J. C. (1991) · Cell · doi:10.1016/0092-8674(91)90293-8 · Cited by 880
Gene inhibition using antisense oligodeoxynucleotides
Wagner, R. W. (1994) · Nature · doi:10.1038/372333a0 · Cited by 736
Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA.
Behr, J. P., Demeneix, B., Loeffler, J. P., & Perez-Mutul, J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.6982 · Cited by 719
Cited by
Nonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366
A peptide carrier for the delivery of biologically active proteins into mammalian cells
Morris, M. C., Depollier, J., Mery, J., Heitz, F., & Divita, G. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1173 · Cited by 1,018
Self-citationPolyethylenimine-based non-viral gene delivery systems
Lungwitz, U., Breunig, M., Blunk, T., & Göpferich, A. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.11.011 · Cited by 983
Cell-Penetrating Peptides: Design, Synthesis, and Applications
Copolovici, D. M., Langel, K., Eriste, E., & Langel, Ü. (2014) · ACS Nano · doi:10.1021/nn4057269 · Cited by 963
Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics
Heitz, F., Morris, M. C., & Divita, G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00057.x · Cited by 867
Self-citationCell‐penetrating peptides: 20 years later, where do we stand?
Bechara, C., & Sagan, S. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.04.031 · Cited by 857
Cell-penetrating peptides: classes, origin, and current landscape
Milletti, F. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.002 · Cited by 813
Lindgren, M., Hällbrink, M., Prochiantz, A., & Langel, Ü. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01447-4 · Cited by 803
Cell-penetrating peptides: mechanism and kinetics of cargo delivery
Zorko, M., & Langel, Ü. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.010 · Cited by 799
Circular Dichroism Techniques: Biomolecular and Nanostructural Analyses‐ A Review
Ranjbar, B., & Gill, P. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00847.x · Cited by 682
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery
Habibi, N., Kamaly, N., Memic, A., & Shafiee, H. (2016) · Nano Today · doi:10.1016/j.nantod.2016.02.004 · Cited by 619
Cell-penetrating peptides: tools for intracellular delivery of therapeutics
Deshayes, S., Morris, M. C., Divita, G., & Heitz, F. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5109-0 · Cited by 483
Self-citationSimeoni, F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg385 · Cited by 480
Delivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers
Torchilin, V. P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.008 · Cited by 449
Cell-penetrating and cell-targeting peptides in drug delivery
Vivès, E., Schmidt, J., & Pèlegrin, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.03.001 · Cited by 441
Cell-penetrating peptides and antimicrobial peptides: how different are they?
Henriques, S. T., Melo, M. N., & Castanho, M. A. R. B. (2006) · Biochemical Journal · doi:10.1042/bj20061100 · Cited by 412
Cell‐penetrating peptides: from molecular mechanisms to therapeutics
Morris, M. C., Deshayes, S., Heitz, F., & Divita, G. (2008) · Biology of the Cell · doi:10.1042/bc20070116 · Cited by 361
Self-citationA New Potent Secondary Amphipathic Cell–penetrating Peptide for siRNA Delivery Into Mammalian Cells
Crombez, L., Aldrian-Herrada, G., Konate, K., Nguyen, Q. N., McMaster, G. K., Brasseur, R., Heitz, F., & Divita, G. (2009) · Molecular Therapy · doi:10.1038/mt.2008.215 · Cited by 346
Gilbert, E. R., Wong, E. A., & Webb, K. E. (2008) · Journal of Animal Science · doi:10.2527/jas.2007-0826 · Cited by 337
Secondary structure of cell-penetrating peptides controls membrane interaction and insertion
Eiríksdóttir, E., Konate, K., Langel, Ü., Divita, G., & Deshayes, S. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.03.005 · Cited by 323
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Cell-Penetrating Peptides: Design Strategies beyond Primary Structure and Amphipathicity
Kalafatovic, D., & Giralt, E. (2017) · Molecules · doi:10.3390/molecules22111929 · Cited by 302
Nanopreparations for organelle-specific delivery in cancer
Biswas, S., & Torchilin, V. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.004 · Cited by 292
Cell-Penetrating Peptides—Mechanisms of Cellular Uptake and Generation of Delivery Systems
Trabulo, S., Cardoso, A. L., Mano, M., & De Lima, M. C. P. (2010) · Pharmaceuticals · doi:10.3390/ph3040961 · Cited by 290
Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides
Dissanayake, S., Denny, W. A., Gamage, S., & Sarojini, V. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.006 · Cited by 280
Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies
Habault, J., & Poyet, J.-L. (2019) · Molecules · doi:10.3390/molecules24050927 · Cited by 280
WEINBERG, M. S., VILLENEUVE, L. M., EHSANI, A., AMARZGUIOUI, M., AAGAARD, L., CHEN, Z.-X., RIGGS, A. D., ROSSI, J. J., & MORRIS, K. V. (2006) · RNA · doi:10.1261/rna.2235106 · Cited by 275
Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides
Meade, B. R., & Dowdy, S. F. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.004 · Cited by 274
Fischer, R., Fotin‐Mleczek, M., Hufnagel, H., & Brock, R. (2005) · ChemBioChem · doi:10.1002/cbic.200500044 · Cited by 269
Antimicrobial peptides with cell-penetrating peptide properties and vice versa
Splith, K., & Neundorf, I. (2011) · European Biophysics Journal · doi:10.1007/s00249-011-0682-7 · Cited by 265
New Basic Membrane-Destabilizing Peptides for Plasmid-Based Gene Delivery in Vitro and in Vivo
Rittner, K., Benavente, A., Bompard-Sorlet, A., Heitz, F., Divita, G., Brasseur, R., & Jacobs, E. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0523 · Cited by 257
Cell-penetrating peptides transport therapeutics into cells
Ramsey, J. D., & Flynn, N. H. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.003 · Cited by 256
Ziegler, A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.005 · Cited by 255
Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape
Endoh, T., & Ohtsuki, T. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.005 · Cited by 242
McCarthy, H. O., McCaffrey, J., McCrudden, C. M., Zholobenko, A., Ali, A. A., McBride, J. W., Massey, A. S., Pentlavalli, S., Chen, K.-H., Cole, G., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.048 · Cited by 216
“The formation of polyplexes with theMPG peptide is dependent on counter-ion condensation, and studies have shown that this peptide can deliver both siRNA and DNA in vitro after just 1 h [2,3].”
BackgroundGene Delivery Technologies with Applications in Microalgal Genetic Engineering
Gutiérrez, S., & Lauersen, K. J. (2021) · Biology · doi:10.3390/biology10040265 · Cited by 68
Cell penetrating peptide: A potent delivery system in vaccine development
Hasannejad-Asl, B., Pooresmaeil, F., Takamoli, S., Dabiri, M., & Bolhassani, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072685 · Cited by 40
Metadata
- Authors
- Morris, M.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-07-15
- Volume
- 25
- Issue
- 14
- Pages
- 2730-2736
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2108224709
- Cited by
- 535
- References
- 25
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.